← Eichor
Study identifier: NCT07443579 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography

Condition: Breast Cancer · Breast Cancer Recurrence · Post Treatment Surveillance  ·  Sponsor: Royal College of Surgeons, Ireland

PhaseNA
Planned participants400
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective, single-centre, parallel-group randomised controlled trial evaluates the optimal sequencing of mammography views in women with a history of breast cancer undergoing surveillance mammography. Women treated with breast-conserving surgery within the previous five years will be randomised 1:1:1:1 to one of four mammography view sequencing groups. The primary objective is to compare patient-reported pain and satisfaction across sequencing groups. Secondary objectives include comparison of image quality (PGMI scoring), compression force, and breast thickness. A total of 400 participants will be enrolled at Beaumont Hospital Breast Care Centre over 2.5 years.

This description comes directly from the study's public registry record.

Talk to the study team

Prof Nuala Healy  ·  +35318093000  ·  nualahealy@rcsi.ie

Always discuss trial participation with your own doctor first.

Locations (1)

Beaumont RCSI Cancer CentreBeaumont, Dublin, IrelandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07443579